When should you increase your Wegovy dose — and what the guidance actually says

What the STEP 1 trial tells us about the titration timeline

The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and produced an average body-weight reduction of around 15% at the 2.4 mg maintenance dose. That result came through a structured, gradual escalation, not from jumping to the highest dose quickly. Participants moved through each dose level on a roughly monthly basis, giving the body time to settle before the next increase. The titration design was deliberate: faster increases meant more people stopped treatment early because of gastrointestinal side effects.

That context matters if you are sitting with your current pen wondering whether it is time to move up. The schedule is not arbitrary. It reflects what actually happened in the trial population, and slower progression was associated with better long-term adherence. If 68 weeks sounds like a long time, it is worth remembering that sustainable weight loss at this scale takes time by design.

The dose steps are 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. Each is a minimum of four weeks before any increase is considered, and if you are unsure how often you should increase Wegovy, the short answer is that four weeks is the floor, not the target. Many people spend longer at one or more steps, and that is entirely normal and often clinically preferable.

Reasons your prescriber might delay a dose increase

It is completely understandable to feel impatient, especially in the first few months when you are not yet at the full maintenance dose and results may feel modest. Most people who contact our prescribers about this are not being impatient; they are just unsure what the right signal looks like. That uncertainty is worth addressing directly.

Your prescriber will typically recommend staying at your current dose for longer if: nausea or vomiting has been more than mild; you have had significant diarrhoea or are struggling to stay hydrated; your appetite suppression is already marked and a higher dose feels unnecessary right now; or there has been any change in your health that warrants caution. These are clinical calls, not bureaucratic ones.

There is also no evidence that skipping a step or rushing titration improves outcomes, and some evidence that it worsens tolerability. If a particular dose level has been comfortable and effective, your prescriber may suggest spending a full eight weeks there rather than four. You can read more about the full structure of the schedule on our Wegovy doses overview, which covers what each level looks like in practical terms.

When a dose increase is appropriate, and what a review looks like

In broad terms, understanding when you should increase your Wegovy dose comes down to having completed at least four weeks at the current level, keeping side effects tolerable, and your prescriber judging that moving up is in your clinical interest. The NICE appraisal of semaglutide (TA875) frames the medicine within a broader treatment programme (not as a standalone dose-management exercise) which is why aftercare and prescriber oversight matter throughout, not just at the start.

At nume, a clinical review happens before every dose change. A real prescriber reads your update; there is no automated system that simply triggers the next pen. You will typically be asked how you have been tolerating the current dose, whether you have had any new symptoms, and whether your weight trajectory has been moving as expected. If the picture is clear and all the right signals are there, progression is approved the same day. If there is any reason to pause, your prescriber will explain it, and our guidance on when you increase your Wegovy dose covers what that decision-making process looks like in more detail.

For context on what private semaglutide treatment involves more broadly, including what an ongoing prescription costs in the UK, our Wegovy pricing page covers what is included in a full treatment plan. Questions about starting the process from scratch are answered on the Wegovy treatment page.

The 7.2 mg dose and what it means for titration decisions

Since April 2026, a higher 7.2 mg maintenance dose has been available, the MHRA approved the dedicated single-dose 7.2 mg pen on 14 April 2026 for adults with a BMI of 30 or above. Trial data suggests average weight loss of around 20.7% over 72 weeks at this level, which brings it closer to tirzepatide's results in head-to-head data. The titration pathway still starts at 0.25 mg; the 7.2 mg pen is the end of a longer journey, not a shortcut.

Whether this higher dose is right for you depends on a full clinical review. People already established on 2.4 mg who have tolerated that dose well may be candidates, but this is not a decision to make based on a headline figure. The same principle applies here as at every earlier step: your prescriber weighs up tolerability, your health picture as a whole, and what the evidence actually supports for your situation.

If you have questions about your current treatment or want to understand your options, you can also browse our frequently asked questions or reach out via our contact page. When you are ready to discuss your dose with a prescriber directly, the right place to start is a free consultation with our clinical team.